Influence of Preoperative Immunomodulation by Oral Impact on Postoperative Complications Following Cystectomies & Nephrectomies
Launched by CENTRE HOSPITALIER INTERCOMMUNAL ROBERT BALLANGER · Aug 25, 2022
Trial Information
Current as of November 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special oral supplement called Oral Impact might help patients before they have major urological surgeries, like cystectomies (removal of the bladder) or nephrectomies (removal of a kidney). The goal is to see if taking this supplement can reduce complications after surgery and help patients recover more quickly, so they spend less time in the hospital.
To participate, you need to be at least 18 years old and scheduled for one of these surgeries. You should also be able to take the Oral Impact supplement for seven days before your surgery. However, if you have a weakened immune system, certain infections, or are undergoing urgent surgery, you wouldn’t be eligible. If you join the trial, you can expect to be part of a study that aims to improve outcomes for patients undergoing these types of surgeries, and you'll be contributing to valuable research that could benefit others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years of age and older
- • Scheduled major urological surgery: scheduled: cystectomy, nephrectomy, other laparotomies.
- • Having expressed their free and informed consent.
- • Affiliated to a social security scheme
- Exclusion Criteria:
- • Immune deficiency.
- • HIV infection.
- • Curative surgery for chronic urinary tract infection.
- • Urgent surgery.
- • Inability to take oral impact 7 days before surgery.
- • Unstable psychiatric state.
- • Infection with COVID 19 during postoperative stay.
About Centre Hospitalier Intercommunal Robert Ballanger
The Centre Hospitalier Intercommunal Robert Ballanger is a leading healthcare institution dedicated to providing high-quality medical services and advancing clinical research. Located in Aulnay-sous-Bois, France, this hospital is committed to improving patient care through innovative research initiatives and collaboration with various medical professionals. As a clinical trial sponsor, the Centre Hospitalier Intercommunal Robert Ballanger aims to enhance medical knowledge and treatment options across diverse therapeutic areas, ensuring a focus on patient safety and ethical standards throughout its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aulnay Sous Bois, France
Montreuil, France
Patients applied
Trial Officials
Serge NDOKO, MD
Principal Investigator
Robert ballanger
MAtthieu CAMBY, MD
Principal Investigator
Centre Hospitalier Intercommunal André Grégoire
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials